<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD04950000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P10912</UniProt_ID>
  <Seq_Length>638</Seq_Length>
  <Molecule_Weight>71500</Molecule_Weight>
  <KEGG_ID>hsa:2690</KEGG_ID>
  <Orthology_ID>K05080</Orthology_ID>
  <EBI_ID>EBI-286316</EBI_ID>
  <Function_Summary>Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway (By similarity).The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling.Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling.</Function_Summary>
  <Pfam_ID>PF09067:EpoR_lig-bind@@PF00041:fn3</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Somatotropin receptor</Alias>
      <Alias>Growth hormone-binding protein</Alias>
      <Alias>GH-binding protein</Alias>
      <Alias>GHBP</Alias>
      <Alias>Serum-binding protein</Alias>
      <Alias>GH receptor</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a proline-rich region, i.e. a region that contains a high proportion of proline residues, in a protein.</Detail>
      <Keyword>Proline-rich region binding</Keyword>
      <Ontology_ID>GO:0070064</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an identical protein to form a homodimer.</Detail>
      <Keyword>Protein homodimerization activity</Keyword>
      <Ontology_ID>GO:0042803</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any growth factor, proteins or polypeptides that stimulate a cell or organism to grow or proliferate.</Detail>
      <Keyword>Growth factor binding</Keyword>
      <Ontology_ID>GO:0019838</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate.</Detail>
      <Keyword>Protein kinase binding</Keyword>
      <Ontology_ID>GO:0019901</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any peptide with hormonal activity in animals.</Detail>
      <Keyword>Peptide hormone binding</Keyword>
      <Ontology_ID>GO:0017046</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>170</Position>
      <Original>Asp</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>68</Position>
      <Original>Trp</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>58</Position>
      <Original>Ser</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>579</Position>
      <Original>Pro</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>56</Position>
      <Original>Cys</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>244</Position>
      <Original>Ser</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>179</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>229</Position>
      <Original>Arg</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>242</Position>
      <Original>Glu</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>440</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>143</Position>
      <Original>Val</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>149</Position>
      <Original>Pro</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>465</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>114</Position>
      <Original>Phe</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>544</Position>
      <Original>Ile</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>262</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>495</Position>
      <Original>Pro</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>89</Position>
      <Original>Arg</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>162</Position>
      <Original>Val</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>229</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>162</Position>
      <Original>Val</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>226</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>179</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>62</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>172</Position>
      <Original>Gln</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>162</Position>
      <Original>Val</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>173</Position>
      <Original>Val</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>171</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The process of introducing a phosphate group to a tyrosine residue of a JAK2 (Janus Activated Kinase 2) protein, thereby activating it.</Detail>
      <Keyword>Activation of JAK2 kinase activity</Keyword>
      <Ontology_ID>GO:0042977</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving isoleucine, (2R*,3R*)-2-amino-3-methylpentanoic acid.</Detail>
      <Keyword>Isoleucine metabolic process</Keyword>
      <Ontology_ID>GO:0006549</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the introduction of a phosphate group to a tyrosine residue of a Stat5 protein.</Detail>
      <Keyword>Positive regulation of tyrosine phosphorylation of Stat5 protein</Keyword>
      <Ontology_ID>GO:0042523</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving allantoin, (2,5-dioxo-4-imidazolidinyl)urea, an intermediate or end product of purine catabolism.</Detail>
      <Keyword>Allantoin metabolic process</Keyword>
      <Ontology_ID>GO:0000255</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving valine, 2-amino-3-methylbutanoic acid.</Detail>
      <Keyword>Valine metabolic process</Keyword>
      <Ontology_ID>GO:0006573</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving citrate, 2-hydroxy-1,2,3-propanetricarboyxlate. Citrate is widely distributed in nature and is an important intermediate in the TCA cycle and the glyoxylate cycle.</Detail>
      <Keyword>Citrate metabolic process</Keyword>
      <Ontology_ID>GO:0006101</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which STAT proteins (Signal Transducers and Activators of Transcription) are activated by members of the JAK (janus activated kinase) family of tyrosine kinases, following the binding of physiological ligands to the growth hormone receptor. Once activated, STATs dimerize and translocate to the nucleus and modulate the expression of target genes.</Detail>
      <Keyword>JAK-STAT cascade involved in growth hormone signaling pathway</Keyword>
      <Ontology_ID>GO:0060397</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving taurine (2-aminoethanesulfonic acid), a sulphur-containing amino acid derivative important in the metabolism of fats.</Detail>
      <Keyword>Taurine metabolic process</Keyword>
      <Ontology_ID>GO:0019530</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the introduction of a phosphate group to a tyrosine residue of a Stat3 protein.</Detail>
      <Keyword>Positive regulation of tyrosine phosphorylation of Stat3 protein</Keyword>
      <Ontology_ID>GO:0042517</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of the insulin-like growth factor receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Insulin-like growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0048009</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving fatty acids, aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis.</Detail>
      <Keyword>Fatty acid metabolic process</Keyword>
      <Ontology_ID>GO:0006631</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways in multicellular organisms that occur at the tissue, organ, or organismal level. These processes, unlike cellular metabolism, can include transport of substances between cells when that transport is required.</Detail>
      <Keyword>Multicellular organismal metabolic process</Keyword>
      <Ontology_ID>GO:0044236</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving succinate, also known as butanedioate or ethane dicarboxylate, the dianion of succinic acid. Succinate is an important intermediate in metabolism and a component of the TCA cycle.</Detail>
      <Keyword>Succinate metabolic process</Keyword>
      <Ontology_ID>GO:0006105</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of growth of an organism to reach its usual body size.</Detail>
      <Keyword>Positive regulation of multicellular organism growth</Keyword>
      <Ontology_ID>GO:0040018</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The initiation of the activity of the inactive enzyme MAP kinase by phosphorylation by a MAPKK.</Detail>
      <Keyword>Activation of MAPK activity</Keyword>
      <Ontology_ID>GO:0000187</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving creatine (N-(aminoiminomethyl)-N-methylglycine), a compound synthesized from the amino acids arginine, glycine, and methionine that occurs in muscle.</Detail>
      <Keyword>Creatine metabolic process</Keyword>
      <Ontology_ID>GO:0006600</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving creatinine, 2-amino-1,5-dihydro-1-methyl-4H-imidazol-4-one, an end product of creatine metabolism and a normal constituent of urine.</Detail>
      <Keyword>Creatinine metabolic process</Keyword>
      <Ontology_ID>GO:0046449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by estradiol, a C18 steroid hormone hydroxylated at C3 and C17 that acts as a potent estrogen.</Detail>
      <Keyword>Response to estradiol stimulus</Keyword>
      <Ontology_ID>GO:0032355</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving oxoglutarate, the dianion of 2-oxoglutaric acid. It is a key constituent of the TCA cycle and a key intermediate in amino-acid metabolism.</Detail>
      <Keyword>2-oxoglutarate metabolic process</Keyword>
      <Ontology_ID>GO:0006103</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving oxaloacetate, the anion of oxobutanedioic acid, an important intermediate in metabolism, especially as a component of the TCA cycle.</Detail>
      <Keyword>Oxaloacetate metabolic process</Keyword>
      <Ontology_ID>GO:0006107</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A receptor-mediated endocytosis process that results in the movement of receptors from the plasma membrane to the inside of the cell. The process begins when cell surface receptors are monoubiquitinated following ligand-induced activation; receptors are subsequently taken up into endocytic vesicles and targeted to the lysosome or vacuole for degradation. Receptor internalization serves as a mechanism to downregulate receptor signaling.</Detail>
      <Keyword>Receptor internalization</Keyword>
      <Ontology_ID>GO:0031623</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A vesicle-mediated transport process in which cells take up external materials or membrane constituents by the invagination of a small region of the plasma membrane to form a new membrane-bounded vesicle.</Detail>
      <Keyword>Endocytosis</Keyword>
      <Ontology_ID>GO:0006897</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cycloheximide stimulus. Cycloheximide (actidione) is an antibiotic produced by some Streptomyces species which interferes with protein synthesis in eukaryotes.</Detail>
      <Keyword>Response to cycloheximide</Keyword>
      <Ontology_ID>GO:0046898</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <Molecule_Seq>
    <Protein_Seq>MDLWQLLLTLALAGSSDAFSGSEATAAILSRAPWSLQSVNPGLKTNSSKEPKFTKCRSPERETFSCHWTDEVHHGTKNLGPIQLFYTRRNTQEWTQEWKECPDYVSAGENSCYFNSSFTSIWIPYCIKLTSNGGTVDEKCFSVDEIVQPDPPIALNWTLLNVSLTGIHADIQVRWEAPRNADIQKGWMVLEYELQYKEVNETKWKMMDPILTTSVPVYSLKVDKEYEVRVRSKQRNSGNYGEFSEVLYVTLPQMSQFTCEEDFYFPWLLIIIFGIFGLTVMLFVFLFSKQQRIKMLILPPVPVPKIKGIDPDLLKEGKLEEVNTILAIHDSYKPEFHSDDSWVEFIELDIDEPDEKTEESDTDRLLSSDHEKSHSNLGVKDGDSGRTSCCEPDILETDFNANDIHEGTSEVAQPQRLKGEADLLCLDQKNQNNSPYHDACPATQQPSVIQAEKNKPQPLPTEGAESTHQAAHIQLSNPSSLSNIDFYAQVSDITPAGSVVLSPGQKNKAGMSQCDMHPEMVSLCQENFLMDNAYFCEADAKKCIPVAPHIKVESHIQPSLNQEDIYITTESLTTAAGRPGTGEHVPGSEMPVPDYTSIHIVQSPQGLILNATALPLPDKEFLSSCGYVSTDQLNKIMP</Protein_Seq>
    <DNA_Seq>CGGCGGCGGCGGCGGCAGCGGCAGCAGCAGCTGCTACAGTGGCGGTGGCGGCGGCGGCTGCTGCTGAGCCCGGGCGGCGGCGGGGACCCCGGGCTGGGGCCACGCGGGCCGGAGGCCCCGGCACCATTGGCCCCAGCGCAGACGCGAACCCGCGCTCTCTGATCAGAGGCGAAGCTCGGAGGTCCTACAGGTATGGATCTCTGGCAGCTGCTGTTGACCTTGGCACTGGCAGGATCAAGTGATGCTTTTTCTGGAAGTGAGGCCACAGCAGCTATCCTTAGCAGAGCACCCTGGAGTCTGCAAAGTGTTAATCCAGGCCTAAAGACAAATTCTTCTAAGGAGCCTAAATTCACCAAGTGCCGTTCACCTGAGCGAGAGACTTTTTCATGCCACTGGACAGATGAGGTTCATCATGGTACAAAGAACCTAGGACCCATACAGCTGTTCTATACCAGAAGGAACACTCAAGAATGGACTCAAGAATGGAAAGAATGCCCTGATTATGTTTCTGCTGGGGAAAACAGCTGTTACTTTAATTCATCGTTTACCTCCATCTGGATACCTTATTGTATCAAGCTAACTAGCAATGGTGGTACAGTGGATGAAAAGTGTTTCTCTGTTGATGAAATAGTGCAACCAGATCCACCCATTGCCCTCAACTGGACTTTACTGAACGTCAGTTTAACTGGGATTCATGCAGATATCCAAGTGAGATGGGAAGCACCACGCAATGCAGATATTCAGAAAGGATGGATGGTTCTGGAGTATGAACTTCAATACAAAGAAGTAAATGAAACTAAATGGAAAATGATGGACCCTATATTGACAACATCAGTTCCAGTGTACTCATTGAAAGTGGATAAGGAATATGAAGTGCGTGTGAGATCCAAACAACGAAACTCTGGAAATTATGGCGAGTTCAGTGAGGTGCTCTATGTAACACTTCCTCAGATGAGCCAATTTACATGTGAAGAAGATTTCTACTTTCCATGGCTCTTAATTATTATCTTTGGAATATTTGGGCTAACAGTGATGCTATTTGTATTCTTATTTTCTAAACAGCAAAGGATTAAAATGCTGATTCTGCCCCCAGTTCCAGTTCCAAAGATTAAAGGAATCGATCCAGATCTCCTCAAGGAAGGAAAATTAGAGGAGGTGAACACAATCTTAGCCATTCATGATAGCTATAAACCCGAATTCCACAGTGATGACTCTTGGGTTGAATTTATTGAGCTAGATATTGATGAGCCAGATGAAAAGACTGAGGAATCAGACACAGACAGACTTCTAAGCAGTGACCATGAGAAATCACATAGTAACCTAGGGGTGAAGGATGGCGACTCTGGACGTACCAGCTGTTGTGAACCTGACATTCTGGAGACTGATTTCAATGCCAATGACATACATGAGGGTACCTCAGAGGTTGCTCAGCCACAGAGGTTAAAAGGGGAAGCAGATCTCTTATGCCTTGACCAGAAGAATCAAAATAACTCACCTTATCATGATGCTTGCCCTGCTACTCAGCAGCCCAGTGTTATCCAAGCAGAGAAAAACAAACCACAACCACTTCCTACTGAAGGAGCTGAGTCAACTCACCAAGCTGCCCATATTCAGCTAAGCAATCCAAGTTCACTGTCAAACATCGACTTTTATGCCCAGGTGAGCGACATTACACCAGCAGGTAGTGTGGTCCTTTCCCCGGGCCAAAAGAATAAGGCAGGGATGTCCCAATGTGACATGCACCCGGAAATGGTCTCACTCTGCCAAGAAAACTTCCTTATGGACAATGCCTACTTCTGTGAGGCAGATGCCAAAAAGTGCATCCCTGTGGCTCCTCACATCAAGGTTGAATCACACATACAGCCAAGCTTAAACCAAGAGGACATTTACATCACCACAGAAAGCCTTACCACTGCTGCTGGGAGGCCTGGGACAGGAGAACATGTTCCAGGTTCTGAGATGCCTGTCCCAGACTATACCTCCATTCATATAGTACAGTCCCCACAGGGCCTCATACTCAATGCGACTGCCTTGCCCTTGCCTGACAAAGAGTTTCTCTCATCATGTGGCTATGTGAGCACAGACCAACTGAACAAAATCATGCCTTAGCCTTTCTTTGGTTTCCCAAGAGCTACGTATTTAATAGCAAAGAATTGACTGGGGCAATAACGTTTAAGCCAAAACAATGTTTAAACCTTTTTTGGGGGAGTGACAGGATGGGGTATGGATTCTAAAATGCCTTTTCCCAAAATGTTGAAATATGATGTTAAAAAAATAAGAAGAATGCTTAATCAGATAGATATTCCTATTGTGCAATGTAAATATTTTAAAGAATTGTGTCAGACTGTTTAGTAGCAGTGATTGTCTTAATATTGTGGGTGTTAATTTTTGATACTAAGCATTGAATGGCTATGTTTTTAATGTATAGTAAATCACGCTTTTTGAAAAAGCGAAAAAATCAGGTGGCTTTTGCGGTTCAGGAAAATTGAATGCAAACCATAGCACAGGCTAATTTTTTGTTGTTTCTTAAATAAGAAACTTTTTTATTTAAAAAACTAAAAACTAGAGGTGAGAAATTTAAACTATAAGCAAGAAGGCAAAAATAGTTTGGATATGTAAAACATTTATTTTGACATAAAGTTGATAAAGATTTTTTAATAATTTAGACTTCAAGCATGGCTATTTTATATTACACTACACACTGTGTACTGCAGTTGGTATGACCCCTCTAAGGAGTGTAGCAACTACAGTCTAAAGCTGGTTTAATGTTTTGGCCAATGCACCTAAAGAAAAACAAACTCGTTTTTTACAAAGCCCTTTTATACCTCCCCAGACTCCTTCAACAATTCTAAAATGATTGTAGTAATCTGCATTATTGGAATATAATTGTTTTATCTGAATTTTTAAACAAGTATTTGTTAATTTAGAAAACTTTAAAGCGTTTGCACAGATCAACTTACCAGGCACCAAAAGAAGTAAAAGCAAAAAAGAAAACCTTTCTTCACCAAATCTTGGTTGATGCCAAAAAAAAATACATGCTAAGAGAAGTAGAAATCATAGCTGGTTCACACTGACCAAGATACTTAAGTGCTGCAATTGCACGCGGAGTGAGTTTTTTAGTGCGTGCAGATGGTGAGAGATAAGATCTATAGCCTCTGCAGCGGAATCTGTTCACACCCAACTTGGTTTTGCTACATAATTATCCAGGAAGGGAATAAGGTACAAGAAGCATTTTGTAAGTTGAAGCAAATCGAATGAAATTAACTGGGTAATGAAACAAAGAGTTCAAGAAATAAGTTTTTGTTTCACAGCCTATAACCAGACACATACTCATTTTTCATGATAATGAACAGAACATAGACAGAAGAAACAAGGTTTTCAGTCCCCACAGATAACTGAAAATTATTTAAACCGCTAAAAGAAACTTTCTTTCTCACTAAATCTTTTATAGGATTTATTTAAAATAGCAAAAGAAGAAGTTTCATCATTTTTTACTTCCTCTCTGAGTGGACTGGCCTCAAAGCAAGCATTCAGAAGAAAAAGAAGCAACCTCAGTAATTTAGAAATCATTTTGCAATCCCTTAATATCCTAAACATCATTCATTTTTGTTGTTGTTGTTGTTGTTGAGACAGAGTCTCGCTCTGTCGCCAGGCTAGAGTGCGGTGGCGCGATCTTGACTCACTGCAATCTCCACCTCCCACAGGTTCAGGCGATTCCCGTGCCTCAGCCTCCTGAGTAGCTGGGACTACAGGCACGCACCACCATGCCAGGCTAATTTTTTTGTATTTTAGCAGAGACGGGGTTTCACCATGTTGGCCAGGATGGTCTCGATCTCCTGACCTCGTGATCCACCCGACTCGGCCTCCCAAAGTGCTGGGATTACAGGTGTAAGCCACCGTGCCCAGCCCTAAACATCATTCTTGAGAGCATTGGGATATCTCCTGAAAAGGTTTATGAAAAAGAAGAATCTCATCTCAGTGAAGAATACTTCTCATTTTTTAAAAAAGCTTAAAACTTTGAAGTTAGCTTTAACTTAAATAGTATTTCCCATTTATCGCAGACCTTTTTTAGGAAGCAAGCTTAATGGCTGATAATTTTAAATTCTCTCTCTTGCAGGAAGGACTATGAAAAGCTAGAATTGAGTGTTTAAAGTTCAACATGTTATTTGTAATAGATGTTTGATAGATTTTCTGCTACTTTGCTGCTATGGTTTTCTCCAAGAGCTACATAATTTAGTTTCATATAAAGTATCATCAGTGTAGAACCTAATTCAATTCAAAGCTGTGTGTTTGGAAGACTATCTTACTATTTCACAACAGCCTGACAACATTTCTATAGCCAAAAATAGCTAAATACCTCAATCAGTCTCAGAATGTCATTTTGGTACTTTGGTGGCCACATAAGCCATTATTCACTAGTATGACTAGTTGTGTCTGGCAGTTTATATTTAACTCTCTTTATGTCTGTGGATTTTTTCCTTCAAAGTTTAATAAATTTATTTTCTTGGATTCCTGATAGTGTGCTTCTGTTATCAAACACCAACATAAAAATGATCTAAACCA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Widely expressed</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular region</CellLocal>
      <Ontology_ID>GO:0005576</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell membrane</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell surface</CellLocal>
      <Ontology_ID>GO:0009986</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Integral to plasma membrane</CellLocal>
      <Ontology_ID>GO:0005887</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Integral to membrane</CellLocal>
      <Ontology_ID>GO:0016021</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Growth hormone receptor complex</CellLocal>
      <Ontology_ID>GO:0070195</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Membrane</CellLocal>
      <Ontology_ID>GO:0016020</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular space</CellLocal>
      <Ontology_ID>GO:0005615</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>GHR</Gene_Name>
    <Gene_ID>2690</Gene_ID>
    <Genbank_ACCN>NM_000163</Genbank_ACCN>
    <Protein_ACCN>NP_000154</Protein_ACCN>
    <HGNC_ID>4263</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/2690</Gene_URL>
    <UCSC_ID>uc021xyd.1</UCSC_ID>
    <EMBL_ID>ENSG00000112964</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>Q9HD43</Uniprot_ID>
      <Gene_Name>PTPRH</Gene_Name>
      <EBI_ID>EBI-1267176</EBI_ID>
      <PPI_EBI_URL>EBI-286316,EBI-1267176</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P18031</Uniprot_ID>
      <Gene_Name>PTPN1</Gene_Name>
      <EBI_ID>EBI-968788</EBI_ID>
      <PPI_EBI_URL>EBI-286316,EBI-968788</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P17706</Uniprot_ID>
      <Gene_Name>PTPN2</Gene_Name>
      <EBI_ID>EBI-984930</EBI_ID>
      <PPI_EBI_URL>EBI-286316,EBI-984930</PPI_EBI_URL>
      <Experiment_Number>8</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P16333</Uniprot_ID>
      <Gene_Name>NCK1</Gene_Name>
      <EBI_ID>EBI-389883</EBI_ID>
      <PPI_EBI_URL>EBI-286316,EBI-389883</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P43378</Uniprot_ID>
      <Gene_Name>PTPN9</Gene_Name>
      <EBI_ID>EBI-742898</EBI_ID>
      <PPI_EBI_URL>EBI-286316,EBI-742898</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P23467</Uniprot_ID>
      <Gene_Name>PTPRB</Gene_Name>
      <EBI_ID>EBI-1265766</EBI_ID>
      <PPI_EBI_URL>EBI-286316,EBI-1265766</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q12913</Uniprot_ID>
      <Gene_Name>PTPRJ</Gene_Name>
      <EBI_ID>EBI-2264500</EBI_ID>
      <PPI_EBI_URL>EBI-286316,EBI-2264500</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P26045</Uniprot_ID>
      <Gene_Name>PTPN3</Gene_Name>
      <EBI_ID>EBI-1047946</EBI_ID>
      <PPI_EBI_URL>EBI-286316,EBI-1047946</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q16829</Uniprot_ID>
      <Gene_Name>DUSP7</Gene_Name>
      <EBI_ID>EBI-1265847</EBI_ID>
      <PPI_EBI_URL>EBI-286316,EBI-1265847</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P01241</Uniprot_ID>
      <Gene_Name>GH1</Gene_Name>
      <EBI_ID>EBI-1026046</EBI_ID>
      <PPI_EBI_URL>EBI-286316,EBI-1026046</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9JLI4</Uniprot_ID>
      <Gene_Name>Ncoa6</Gene_Name>
      <EBI_ID>EBI-286271</EBI_ID>
      <PPI_EBI_URL>EBI-286316,EBI-286271</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Increased Responsiveness to Growth Hormone</Disease_Name>
      <Disease_Detail>Increased Responsiveness to Growth Hormone</Disease_Detail>
      <Disease_DB>INC010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/increased_responsiveness_to_growth_hormone?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Short Stature</Disease_Name>
      <Disease_Detail>Short Stature</Disease_Detail>
      <Disease_DB>SHR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/short_stature?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pituitary Adenoma</Disease_Name>
      <Disease_Detail>Pituitary Tumors</Disease_Detail>
      <Disease_DB>PTT006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pituitary_adenoma?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Insulin-Like Growth Factor I Deficiency</Disease_Name>
      <Disease_Detail>Insulin-Like Growth Factor I Deficiency</Disease_Detail>
      <Disease_DB>INS008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/insulin_like_growth_factor_i_deficiency?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Isolated Growth Hormone Deficiency</Disease_Name>
      <Disease_Detail>Isolated Growth Hormone Deficiency</Disease_Detail>
      <Disease_DB>ISL003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/isolated_growth_hormone_deficiency?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Plexiform Neurofibroma</Disease_Name>
      <Disease_Detail>Plexiform Neurofibroma</Disease_Detail>
      <Disease_DB>PLX002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/plexiform_neurofibroma?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Laron Syndrome</Disease_Name>
      <Disease_Detail>Laron Syndrome</Disease_Detail>
      <Disease_DB>LRN002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/laron_syndrome?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Actinic Keratosis</Disease_Name>
      <Disease_Detail>Actinic Keratosis</Disease_Detail>
      <Disease_DB>ACT008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/actinic_keratosis?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypercholesterolemia, Familial, Modifier of</Disease_Name>
      <Disease_Detail>Hypercholesterolemia</Disease_Detail>
      <Disease_DB>HYP574</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypercholesterolemia_familial_modifier_of?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypercholesterolemia, Familial, Due to Ldlr Defect, Modifier of</Disease_Name>
      <Disease_Detail>Hypercholesterolemia</Disease_Detail>
      <Disease_DB>HYP296</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypercholesterolemia_familial_due_to_ldlr_defect_modifier_of?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Osteoporosis</Disease_Name>
      <Disease_Detail>Osteoporosis</Disease_Detail>
      <Disease_DB>OST002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/osteoporosis?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Papilledema</Disease_Name>
      <Disease_Detail>Papilledema</Disease_Detail>
      <Disease_DB>PPL021</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/papilledema?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Noonan Syndrome</Disease_Name>
      <Disease_Detail>Noonan Syndrome</Disease_Detail>
      <Disease_DB>NNN003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/noonan_syndrome?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acromegaly</Disease_Name>
      <Disease_Detail>Acromegaly</Disease_Detail>
      <Disease_DB>ACR007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acromegaly?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Coronary Artery Disease in Familial Hypercholesterolemia, Protection Against</Disease_Name>
      <Disease_Detail>Coronary Artery Disease in Familial Hypercholesterolemia, Protection Against</Disease_Detail>
      <Disease_DB>CRN127</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/coronary_artery_disease_in_familial_hypercholesterolemia_protection_against?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Drug-Induced Hepatitis</Disease_Name>
      <Disease_Detail>Drug-Induced Hepatitis</Disease_Detail>
      <Disease_DB>DRG002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/drug_induced_hepatitis?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypercholesterolemia</Disease_Name>
      <Disease_Detail>Hypercholesterolemia</Disease_Detail>
      <Disease_DB>HYP095</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypercholesterolemia?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Hypercholesterolemia</Disease_Name>
      <Disease_Detail>Familial Hypercholesterolemia</Disease_Detail>
      <Disease_DB>FML021</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_hypercholesterolemia?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Bell's Palsy</Disease_Name>
      <Disease_Detail>Bell's Palsy</Disease_Detail>
      <Disease_DB>BLL003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/bells_palsy?search=GHR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ldl Cholesterol Level Qtl2</Disease_Name>
      <Disease_Detail>Ldl Cholesterol Level Qtl2</Disease_Detail>
      <Disease_DB>LDL001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ldl_cholesterol_level_qtl2?search=GHR#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>1:1 COMPLEX OF HUMAN GROWTH HORMONE MUTANT G120R WITH ITS SOLUBLE BINDING PROTEIN</PDB_Title>
      <PDB_ID>1HWH</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HWH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of an antagonist mutant of human growth hormone, G120R, in complex with its receptor at 2.9 A resolution.</PubMed_Title>
      <Author>Sundstrom, M., et al.</Author>
      <Journal>J.Biol.Chem.(1996)271:32197-32203</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8943276?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN GROWTH HORMONE BOUND TO SINGLE RECEPTOR</PDB_Title>
      <PDB_ID>1A22</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1A22</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity.</PubMed_Title>
      <Author>Clackson, T., et al.</Author>
      <Journal>J.Mol.Biol.(1998)277:1111-1128</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9571026?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>PHAGE DISPLAY DERIVED VARIANT OF HUMAN GROWTH HORMONE COMPLEXED WITH TWO COPIES OF THE EXTRACELLULAR DOMAIN OF ITS RECEPTOR</PDB_Title>
      <PDB_ID>1KF9</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1KF9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of a Phage Display Derived Variant of Human Growth Hormone Complexed to Two Copies of the Extracellular Domain of its Receptor: Evidence for Strong Structural Coupling between Receptor Binding Sites</PubMed_Title>
      <Author>Schiffer, C.A., et al.</Author>
      <Journal>J.Mol.Biol.(2002)316:277-289</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11851338?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A model for growth hormone receptor activation based on subunit rotation within a receptor dimer</PDB_Title>
      <PDB_ID>2AEW</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2AEW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Model for growth hormone receptor activation based on subunit rotation within a receptor dimer.</PubMed_Title>
      <Author>Brown, R.J., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2005)12:814-821</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16116438?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN GROWTH HORMONE AND EXTRACELLULAR DOMAIN OF ITS RECEPTOR: CRYSTAL STRUCTURE OF THE COMPLEX</PDB_Title>
      <PDB_ID>3HHR</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HHR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Human growth hormone and extracellular domain of its receptor: crystal structure of the complex.</PubMed_Title>
      <Author>de Vos, A.M., et al.</Author>
      <Journal>Science(1992)255:306-312</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/1549776?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>1:2 COMPLEX OF HUMAN GROWTH HORMONE WITH ITS SOLUBLE BINDING PROTEIN</PDB_Title>
      <PDB_ID>1HWG</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HWG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of an antagonist mutant of human growth hormone, G120R, in complex with its receptor at 2.9 A resolution.</PubMed_Title>
      <Author>Sundstrom, M., et al.</Author>
      <Journal>J.Biol.Chem.(1996)271:32197-32203</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8943276?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURAL PLASTICITY AT THE HGH:HGHBP INTERFACE</PDB_Title>
      <PDB_ID>1AXI</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AXI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural plasticity in a remodeled protein-protein interface.</PubMed_Title>
      <Author>Atwell, S., et al.</Author>
      <Journal>Science(1997)278:1125-1128</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9353194?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04080</Pathway_ID>
      <Pathway_Title>Neuroactive ligand-receptor interaction</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signaling molecules and interaction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04060</Pathway_ID>
      <Pathway_Title>Cytokine-cytokine receptor interaction</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signaling molecules and interaction</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All beta proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.c.b.d.b.be.html</SCOP_URL>
    <CATH_Class>Class 2: Mainly Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1a22</CATH_URL>
  </Fold>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>